Palisade Bio, Inc. (PALI)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.54
- As of
Kresmion compiles this page from PALI's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
PALISADE BIO, INC. (PALI): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-10.
See the full PALI dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PALI on one page. Preview it with sample data, then open it live with a free account.
Preview the PALI dossierActive signals for PALI
- highCONSENSUS_BUY
3 tracked funds increased PALI this 2026Q2, institutional consensus
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 6.2%, EPS $-0.05 vs $-0.0533 estimate
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +1176% to PALI (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 56% of PALI (2026Q2)
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +358% to PALI (2026Q2)
FREE, NO ACCOUNT
Every signal on PALI, as it fires
You are seeing 5 of 9 signals recorded on PALI since 2026-05-31.
The five above landed across 3 days. The other 4 were recorded on 2 other days. 5 of the 9 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in PALI (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 696389402 · 2026Q2 | $11M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 696389402 · 2026Q2 | $2.4M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 696389402 · 2026Q2 | $2.1M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 696389402 · 2026Q2 | $2M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 696389402 · 2026Q2 | $265K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, PALI
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
PALI against its peers
PALI's return on equity of -13.0% ranks in the 72nd percentile of 22 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | PALI | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 23.0M USD | 12 | 16 |
| Operating margin | n/a | -296.0% | n/a | 14 |
| Net margin | n/a | -263.6% | n/a | 14 |
| Return on equity | -13.0% | -39.1% | 72 | 22 |
| 1 year | -11.0% | -22.3% | 59 | 22 |
Peers (23): XFOR, BCYC, ABEO, IPSC, RCKT, VNDA, NAUT, IKT, BBOT, ANIK, ACIU, SABS, NWBO, ZNTL, PRLD, QTTB, KROS, LXEO, IMRX, LCTX, EYPT, LRMR, UPB. Left out: VCRE (no annual filing), VOGX (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (PALI: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow PALI on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to PALI for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.